SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) November 25, 2002
------------------------------------------------------------------
EXEGENICS INC.
(Exact name of registrant as specified in its charter)
Delaware 333-26078 75-2402409
(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification No.)
2110 Research Row
Dallas, Texas 75235
(Address of principal executive
offices including zip code)
(214) 358-2000
(Registrant's telephone number,
including area code)
N.A.
----
(Former name or former address, if changed since last report)
Item 5. Other Events.
On November 25, 2002, we announced that we and Innovative Drug Delivery Systems,
Inc. ("IDDS") entered into a termination agreement terminating the merger
agreement between the two companies that was entered into on September 19, 2002.
In connection with the termination, we purchased a $500,000 convertible note
from IDDS at face amount and paid IDDS $500,000 to defray, in part, expenses
incurred by IDDS that were associated with this transaction.
In addition, on December 3, 2002, we commenced mailing a letter to our
stockholders regarding the termination of the merger agreement.
A copy of the termination agreement, attached hereto as Exhibit 2.1, a copy of
the joint press release issued on November 25, 2002 announcing the execution of
the termination agreement, attached hereto as Exhibit 99.1, and a copy of the
letter to our stockholders discussing the termination of the merger agreement,
attached hereto as Exhibit 99.2, are incorporated herein by reference. The
foregoing description is qualified in its entirety by reference to the full text
of such exhibits.
Item 7. Financial Statements and Exhibits
(c) Exhibits.
Exhibit No. Description
2.1 Termination Agreement, dated November 25, 2002, by and among us,
IDDS, IDDS Merger Corp. and the stockholders' representatives
listed therein.
99.1 Joint Press Release issued by us and IDDS, dated November 25,
2002.
99.2 Letter to Stockholders, dated December 3, 2002.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
EXEGENICS INC.
(Registrant)
Dated: December 3, 2002 By: /s/ Ronald L. Goode, Ph.D.
---------------- -------------------------------------
Ronald L. Goode, Ph.D.
President and Chief Executive Officer
EXHIBIT INDEX
EXHIBIT
NUMBER DESCRIPTION
------ -----------
2.1 Termination Agreement, dated November 25, 2002, by and among us,
IDDS, IDDS Merger Corp. and the stockholders' representatives
listed therein.
99.1 Joint Press Release issued by us and IDDS, dated November 25,
2002.
99.2 Letter to Stockholders, dated December 3, 2002.